E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) |
|
E.1.1.1 | Medical condition in easily understood language |
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD (following 24 weeks treatment) |
|
E.2.2 | Secondary objectives of the trial |
• Evaluate the safety of UX007 treatment in subjects with LC-FAOD
• Evaluate the effect of UX007 on energy metabolism in LC-FAOD
• Evaluate the impact of UX007 on major clinical events associated with LC-FAOD (following 78 weeks treatment) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Confirmed diagnosis of one of the three most common LC-FAOD disorders: CPT II deficiency, VLCAD deficiency, LCHAD deficiency and TFP deficiency. Diagnosis must be confirmed by results of acylcarnitine profiles, fatty acid oxidation probe studies in cultured fibroblasts, and/or mutation analysis obtained from medical records.
• Male or female, at least 6 months of age
• Willing and able to complete all aspects of the study through the end of the study, including visits and tests, documentation of symptoms and diet, and administration of study medications. If a minor, have a caregiver(s) willing and able to assist in all applicable study requirements.
• Provide written informed consent (subjects aged ≥ 18 years), or provide written assent (where appropriate) and have a legally authorized representative willing and able to provide written informed consent, after the nature of the study has been explained and prior to any research-related procedures
• Willing and able to provide access to medical records charting the last 18-24 months of care prior to the study initiation, or from birth for those subjects less than 18 months of age
• No history of serious adverse reactions or known hypersensitivity to triheptanoin
• Currently managed on a stable treatment regimen (including diet), which may include low-fat/high carbohydrate diet, avoidance of fasting, carnitine and/or MCT oil. The treatment regimen (including diet) should be stable for the last 60 days to assure that changes in the subjects' condition are not confounded by recent changes in the treatment regimen that could affect the 4 week run-in evaluation period. Once
study drug treatment has started, must be willing to maintain all aspects of the subject's treatment regimen and diet unchanged, other than discontinuation of MCT oil, in order to avoid potential variability of response due to variations in dietary intake.
• Have severe LC-FAOD, as evidenced by ANY ONE of the following significant clinical manifestations despite therapy:
- Chronic Elevated CK with Major Clinical Events: Elevated mean CK levels over the last 6 months -1 year (defined as ≥ 2X upper limit of age/gender-matched normal, or ≥ 500 units/L if age-matched reference not established) not associated with an acute rhabdomyolysis event, AND at least two major clinical events (as defined in the protocol) in the last year, or at least four major clinical events over the last two
years,
-Episodic Elevated CK with Reported Muscle Dysfunction: Episodes of elevated CK levels over the last 6 months -1 year (defined as ≥ 2X upper limit of age/gender-matched normal, or ≥ 500 units/L if age-matched reference is not established), AND patient report of frequent muscle fatigue, exercise intolerance, or limitation of exercise,
- Highly Elevated CK but Asymptomatic: More seriously elevated mean CK levels (defined as ≥ 4X upper limit of age/gender-matched normal, or ≥ 1000 units/L if age-matched reference is not established) consistent with substantial chronic muscle rupture over the last 6 months-1 year,
regardless of frequency hospitalizations or ER events,
- Frequent Severe Major Medical Episodes (at least 3 within the past year, or 5 within 2 years) of hypoglycemia, rhabdomyolysis, or exacerbation of CM, requiring ER/acute care visits or hospitalizations,
- Severe Susceptibility to Hypoglycemia (serum glucose <60 mg/dL) after short periods of fasting (less than 4-12 hours, depending on age), with at least 2 events in the last year that require ongoing prophylactic management, OR recurrent symptomatic hypoglycemia (blood glucose levels or clinical symptoms of hypoglycemia) at home requiring intervention ≥ 2 times per week,
- Evidence of Functional CM (with echocardiogram (ECHO) within past 90 days documenting poor EF) requiring ongoing medical management
• Females who have reached menarche must have a negative pregnancy test at Screening. If sexually active, subject must be willing to use acceptable method of contraception and have additional pregnancy tests during the study. |
|
E.4 | Principal exclusion criteria |
• Diagnosis of CACT deficiency, or CPT I
• Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, short- or medium-chain FAOD, ketone body metabolism defect, propionic acidemia or methylmalonic acidemia
• Enrolled in a clinical study involving concurrent use of an investigational drug product within the last 30 days, or unwilling to discontinue use of a prohibited medication or other substance that may confound study objectives
• Unwilling to sign informed consent or release of medical records
• Have any co-morbid conditions, including unstable major organ-system disease(s) that in the opinion of the Investigator, places the subject at increased risk of complications, interferes with study participation or compliance, or confounds study objectives |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Effects of UX007 on LC-FAOD will be assessed by evaluating critical variables of disease impacting three relevant disease areas (skeletal myopathy, hepatic disease, and cardiac disease), along with relevant biomarkers. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
During the Treatment Period (24 weeks), three relevant disease areas will be assessed at Weeks 0, 4, 8, 12, 18, and 24, including 1) Skeletal myopathy: complications such as hypotonia, exercise intolerance, motor development, and functional disability, as well as non-acute CK levels (not associated with an acute rhabdomyolysis event), 2) Hepatic disease: hypoglycemia and related interventions and complications, including hepatomegaly and markers of hepatic function, and 3) Cardiac disease: ejection fraction, shortening fraction, and cardiac biomarkers.
In addition, FAOD-related laboratory measures excluding CK levels will be assessed at Weeks 0, 4, 12 and 24. CK levels will be assessed at Weeks 0, 4, 8, 12, 18, and 24. |
|
E.5.2 | Secondary end point(s) |
- Safety events will be collected as adverse events (AE) or serious adverse events (SAE), including clinical laboratory tests, vital signs, physical examination, and concomitant medications.
- The effects of UX007 treatment on major clinical events will be assessed over the Extension Period (total of 78 weeks). Major events are defined as musculoskeletal, hepatic, and cardiac events caused by LCFAOD, or intercurrent illness complicated by LC-FAOD, resulting in any hospitalization, ER visit, or emergency intervention (any unscheduled administration of therapeutics at home or in the clinic).
- Evaluate the effect of UX007 on energy metabolism in LC-FAOD by measuring plasma UX007, UX007 metabolites. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Safety: Assessed up to Week 78. All AEs will be recorded from the time the subject signs the informed consent.
- The effects of UX007 treatment on major clinical events will be assessed over the Extension Period (total of 78 weeks). Major events are defined as musculoskeletal, hepatic, and cardiac events caused by LC-FAOD, or intercurrent illness complicated by LC-FAOD, resulting in any hospitalization, ER visit, or emergency intervention (any unscheduled administration of therapeutics at home or in the clinic). Assessed at 4-week run-in period, Baseline, and Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60, 78.
- Evaluate the effect of UX007 on energy metabolism in LC-FAOD by measuring plasma UX007, UX007 metabolites, assessed at Weeks 0, 4, 12 and 24. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |